Results 291 to 300 of about 222,465 (345)
Tranexamic acid is toxic on human chondrocytes, in vitro
Benjamin Jacob +7 more
openalex +2 more sources
Abstract Purpose This study aimed to evaluate the radiological and patient‐reported outcome measures (PROMs) following spheroid‐based matrix‐induced autologous chondrocyte implantation combined with autologous bone grafting (MABCI) for the treatment of osteochondral defects of the knee.
Stephan Oehme +7 more
wiley +1 more source
The crosstalk among macrophages, chondrocytes and mesenchymal stem cells in osteoarthritis: the role of extracellular vesicles. [PDF]
Kong H +6 more
europepmc +1 more source
Abstract Purpose To evaluate the safety and efficacy of intra‐articular autologous transplantation of adipose‐derived connective tissue micrografts rich in stromal vascular fraction (CTM‐SVF), obtained using an enzyme‐free system (Hy‐Tissue® SVF) for knee osteoarthritis (OA). Methods Thirty patients (mean age of 53.3 ± 6.4 years) with Kellgren–Lawrence
Laura Mangiavini +11 more
wiley +1 more source
Developing Up-Scale Allogeneic Chondrocyte Therapies Using Juvenile Donor Cartilage. [PDF]
Hulme CH +8 more
europepmc +1 more source
204 AN IKKα ASSOCIATED GENE EXPRESSION PROFILE IN DIFFERENTIATING CHONDROCYTES
Eleonora Olivotto +9 more
openalex +1 more source
Therapeutic Window of Laser Dosimetry for the Treatment of Knee Osteoarthritis
ABSTRACT Objectives We propose a non‐destructive laser method that uses controlled thermomechanical action to treat degenerative cartilage changes. The technique aims to reduce pain, offers a minimally invasive option for early‐ to mid‐stage degeneration, and lessens the need for joint replacement.
Yulia Alexandrovskaya +6 more
wiley +1 more source
Astragaloside IV Alleviates Osteoarthritis by Inhibiting Chondrocyte Ferroptosis via the p53/SLC7A11/GPX4 Axis. [PDF]
Tang Z, Cheng L, Li M, Chen J, Huang C.
europepmc +1 more source
This study develops a biomimetic bilayer scaffold based on gelatin methacryloyl‐ciprofloxacin/polycaprolactone‐collagen (GelMA‐CIP/PCL‐COL), designed to release EGF and TGFβ3 in a controlled manner. The GelMA‐CIP@PVA‐EGF/PCL‐COL@PVA‐TGFβ3 scaffold currently demonstrates sustained delivery of growth factors for 28 days, mechanical properties similar to ...
Hilal Yilmaz +11 more
wiley +1 more source

